Mankind Pharma has announced that a meeting of its Board of Directors is scheduled for May 19, 2026. The primary agenda includes the consideration and approval of the company’s standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. Additionally, the board will discuss the realignment of security cover for existing Non-Convertible Debentures following a recent ₹1,250 crore redemption.
Financial Results Announcement
Mankind Pharma will hold a board meeting on May 19, 2026, to evaluate and approve its audited financial performance for the quarter and fiscal year ending March 31, 2026. Shareholders and investors await these results to gauge the company’s growth trajectory and operational efficiency over the past twelve months.
Strategic Debt Realignment
Beyond the financial results, the board will deliberate on the realignment of security cover for its existing Non-Convertible Debentures (NCDs). This follows the successful redemption of ₹1,250 crore in NCDs completed on April 16, 2026. The realignment involves adjustments for two series of debentures: ISIN INE634S07025 (issued October 16, 2025) and ISIN INE634S07033 (issued October 16, 2025).
Trading Window Update
In accordance with the company’s internal code of conduct for preventing insider trading, the trading window for Mankind Pharma securities remains closed. This restriction will continue through May 21, 2026, ensuring compliance while sensitive financial information is being finalized and reviewed by the board.
Source: BSE
